Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-08-30

Reporting Person: Chopas James George (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-30	Common Stock	A	7600	$0.00	Acquired	7600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-30	Stock Option (right to buy)	$65.41	A	21750	Acquired	2031-08-29	Common Stock (21750)	Direct

Footnotes

F1: The shares are issuable upon vesting of restricted stock units that each represent a contingent right to receive one share of APLS common stock. The restricted stock units vest as to 25% of the shares underlying the award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the award annually until the fourth anniversary of the grant date, subject to continued service.

F2: This option was granted on August 30, 2021 and vests as to 25% of the shares underlying the option on the first anniversary of the grant date and thereafter as to 1/48th of the shares underlying the option monthly until the fourth anniversary of the grant date, subject to continued service.